Research Investments in Global Health (ResIn) is an analysis of investments in infectious disease research.

wordcloud diseasesOur work so far has concentrated on collating information on funded studies from all the major public and philanthropic funders of UK biomedical research and analysing these awards to UK institutions for infectious disease research over the time period of 1997 to 2010. We have published the study findings in numerous peer-reviewed publications. Presentations and downloads of the data can be filtered and customised through the online open-access database. We are currently updating the analysis to include funding information up to 2013, and have also commenced similar analyses in cancer care research. Publications in both these areas will be written across 2015. Further, we are also collecting information on funding awarded to US institutions for infectious disease, plus preliminary work on research funding for an oncology dataset.

 

Recent updates

  • ‘Funding for infectious disease institutions’ paper published in JRSM Open

  • The latest publication to come out of the Research Investments in Global Health study is published today in JRSM Open. It covers the institutions that receive the funding and shows how for some disease areas, there are clear centres of excellence and some clear gaps in their portfolios.

    The abstract is below, and see the full open access paper at the JRSM Open website.


    Systematic analysis of funding awarded to inst
    itutions in the United Kingdom for infectious disease research, 1997–2010

    Objectives This study aimed to assess the research investments made to UK institutions for all infectious disease research and identify the direction of spend by institution.

    Design Systematic analysis. Databases and websites were systematically searched for information on relevant studies funded for the period 1997–2010.

    Setting UK institutions carrying out infectious disease research.

    Participants None.

    Main outcome measures Twenty academic institutions receiving greatest sum investments across infection are included here, also NHS sites, Sanger Institute, Health Protection Agency and the Medical Research Council. We measured total funding, median award size, disease areas and position of research along the R&D value chain.

    Results Included institutions accounted for £2.1 billion across 5003 studies. Imperial College and University of Oxford received the most investment. Imperial College led the most studies. The Liverpool and London Schools of Tropical Medicine had highest median award size, whereas the NHS sites combined had many smaller studies. Sum NHS funding appears to be declining over time, whilst university income is relatively stable. Several institutions concentrate almost exclusively on pre-clinical research. In some areas, there is clearly a leading institution, e.g. Aberdeen and mycology research or UCL and antimicrobial resistance.

    Conclusion UK institutions carry out research across a wide range of infectious disease areas. This analysis can identify centres of excellence and help inform future resource allocation for research priorities. Institutions can use this analysis for establishing expertise within their groups, identifying external collaborators and informing local research strategy.

  • Watch video of ResIn data presented at BSAC meeting

  • ResIn co-founder Michael Head recently presented data on antimicrobial resistance research funding at a British Society for Antimicrobial Chemotherapy meeting, taking place at the Wellcome Collection in London.

    To see what Michael had to say, Click here to visit the website showing the talks presented at the meeting entitled ‘Re-stoking the therapy pipeline – How to stimulate the development of new antibiotics, diagnostics and novel therapies’.

  • Update from ResIn

  • So the update analysis covering 2011-2013 is in full swing, we have written and submitted our first paper using that data (on HIV and other STIs). A norovirus paper shall be submitted soon and an overall summary paper is nearing completion and should be submitted well before Easter. A pneumonia investments paper is also a priority for us, as is an ebola research and implementation investments analysis. We are also beginning to look at ‘investments v research impact’, particularly in the area of bibliometrics, and exploring other areas of work and collaboration with national and international colleagues.